CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION:NDA 20-708/S-005

CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tenative Approval Letter				X
Approvable Letter			X	
Final Printed Labeling		X		
Medical Review(s)	X			
Chemistry Review(s)			X	
EA/FONSI			X	
Pharmacology Review(s)			X	
Statistical Review(s)			X	
Microbiology Review(s)			X	
Clinical Pharmacology Biopharmaceutics Review(s)	X			
Bioequivalence Review(s)			X	
Administrative Document(s)	X			
Correspondence	X			

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

Application Number: NDA 20-708/S-005

Trade Name: Lupron Depot 3-month 11.25 mg.

Generic Name:(leuprolide acetate)

Sponsor:TAP Holdings, Inc.

Approval Date: February 11, 1999

Indication: Provides for revisions to the labeling for Lupro Depot 3-month (leuprolide acetate) 11.25 mg as described below: CLINICAL PHARMACOLOGY section.

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number:NDA 20-708/S-005

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-708/S-005

FEB 11 1999

TAP Holdings Inc.
Attention: Aruna Dabholkar, M.D.
Associate Director, Regulatory Affairs
2355 Waukegan Road
Deerfield, IL 60015

Dear Dr. Dabholkar:

Please refer to your supplemental new drug application dated April 10, 1998, received April 13, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lupron Depot 3-month (leuprolide acetate) 11.25 mg.

We acknowledge receipt of your submissions dated August 7 and December 3, 1998; and February 8, 10 [telefacsimile (2)] and 11 (telefacsimile), 1999.

This supplemental new drug application provides for revisions to the labeling for Lupron Depot 3-month (leuprolide acetate) 11.25 mg as described below:

CLINICAL PHARMACOLOGY section

Pharmacokinetics subsection, "*Metabolism*" subheading

A new second paragraph has been added which reads:

CLINICAL STUDIES section

Endometriosis subsection

A new terminal sentence has been added to the first paragraph which reads:

Uterine Leiomyomata (fibroids) subsection

The fourth paragraph has been revised to add a new second sentence which reads:

The fifth paragraph has been revised to add a new third sentence which reads:

PRECAUTIONS section

subsection **6.**

The first word of the first sentence has been revised from

ADVERSE REACTIONS section

Paragraph five has been revised to add a new terminal sentence which reads:

In addition, Table 3 has been deleted.

CHANGES IN LABORATORY VALUES DURING TREATMENT section

Chemistry subsection

A new subsection, directly following the **Lipids** subsection, has been added and reads:

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted February 10, 1999).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-708/S-005." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Christina Kish, Project Manager, at (301) 827-4260.

Sincerely,

/S/

Lisa D. Rarick, M.D.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research